SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump For President

TRUMP Crypto is experiencing intense volatility and social media attention fueled by reports of an exclusive Mar-a-Lago gala invite for top holders, sparking polarized community debates over its legitimacy and the potential for market manipulation. Detractors and supporters alike are actively clashing over the project's ties to political news and the broader grift allegations surrounding the Trump family brand.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is facing short-term volatility as traders react to reports of a delayed AI model rollout and broader concerns over aggressive capital expenditures. While community sentiment is heavily polarized between skeptics questioning the stock's long-term growth and bullish investors viewing the dip as a prime accumulation opportunity, the active discussion remains centered on the company's competitive positioning in the AI race and its overall fundamental resilience.

Sable Offshore Corp. engages in offshore oil and gas field operations. It focuses on developing the prolific Santa Ynez Unit in federal waters offshore California. The company was founded by James C. Flores on October 16, 2020 and is headquartered in Houston, TX.

Sable Offshore Corp.

Sable Offshore (SOC) is seeing extreme volatility as investors weigh the potential for a massive short squeeze against significant regulatory and legal headwinds. The community is sharply divided between those betting on federal support via the Defense Production Act to bypass California's pipeline restrictions and those concerned about the company's precarious financial position and ongoing environmental litigation.

Volatility Shares Trust - 2x Ether ETF

Volatility Shares 2x Ether ETF

The Volatility Shares 2x Ether ETF ($ETHU) is trending as traders heavily leverage the recent volatility in the underlying crypto market, with the community actively debating the pros and cons of using 2x leveraged products to play Ethereum's price swings versus holding the spot asset or other crypto-exposed stocks. Market participants are intensely focused on the ETF's rapid price action and the impact of volatility decay, with many debating optimal entry points during recent price pullbacks and speculating on whether the current market conditions favor a breakout or further consolidation.

United States Commodity Funds LLC - United States Brent Crude Oil Fund

BNO is trending as investors weigh escalating geopolitical tensions in the Middle East against concerns that high oil prices could dampen corporate earnings and trigger broader economic stress. Community discussion is heavily focused on potential supply disruptions in the Strait of Hormuz, the efficacy of emergency oil reserve releases, and conflicting arguments over whether current market conditions warrant a bullish outlook or suggest an impending price correction.

Canton Coin (CC), the network’s native utility token, was designed to reward real network usage over speculation. It aligns the success of the network with the participants who make it work, fairly rewarding app builders and app users, as well as those operating decentralized infrastructure. The result is a fundamentally different model where rewards flow to those creating value through real activity, not only miners or early investors.

Canton

Canton is drawing significant institutional interest and community excitement due to its role in tokenizing real-world assets and its recent integrations with major financial partners. Investors are closely monitoring the project's increasing utility within the blockchain infrastructure sector, frequently highlighting its recent exchange listings and the potential for long-term growth.

United States Commodity Funds LLC - United States Gasoline Fund LP

United States Gasoline Fund LP

The United States Gasoline Fund LP (UGA) is currently in focus as gasoline prices exhibit significant volatility driven by geopolitical tensions in the Strait of Hormuz and ongoing supply chain concerns. Market participants are actively debating the inflationary impact of rising fuel costs while closely watching technical indicators and institutional strategies for potential shifts in the energy sector.

Invesco DB Multi-Sector Commodity Trust - Invesco DB Agriculture Fund

Invesco DB Agriculture Fund

The Invesco DB Agriculture Fund is trending as investors monitor ongoing supply chain disruptions, extreme weather patterns, and shifting geopolitical trade policies that continue to drive volatility in agricultural commodities. Market participants are actively discussing the fund's role as an inflation hedge amidst broader market uncertainty and the persistent challenges of food price stability.

BlackRock, Inc. engages in the provision of investment, advisory and risk management solutions. Its products include single-asset and multi-asset portfolios. The company was founded by Laurence Douglas Fink in 1988 and is headquartered in New York, NY.

Blackrock Inc.

BlackRock is currently navigating market volatility driven by significant redemption pressure within its private credit funds, forcing the firm to cap withdrawals for its HPS Corporate Lending Fund. Investors are actively debating whether this signals a broader liquidity crisis in the shadow banking sector or if the firm's robust $14 trillion AUM provides sufficient structural resilience to weather the storm.

BlockDAG is a hybrid concept that combines features of both traditional blockchains and DAGs. It retains the benefits of DAGs, such as high scalability and faster transaction processing, while integrating the security and trust of blockchain consensus mechanisms. BlockDAG emerges as a groundbreaking solution, meticulously merging the strengths of both blockchain and DAG architectures. It leverages the robust security and decentralization of blockchains while incorporating the efficient, scalable transaction processing of DAGs. This strategic integration allows blockDAG to handle a significantly higher volume of transactions at faster speeds compared to traditional blockchains. By overcoming the inherent limitations of both technologies, blockDAG paves the way for a future where distributed ledgers can seamlessly scale to meet the ever-growing demands of the cryptocurrency and broader digital landscape.

BlockDAG

BlockDAG is currently trending as users grapple with a frustrating and ongoing token claim process, with many reporting issues connecting wallets and locating their assets. While some of the community remains focused on potential long-term utility and mining growth, others are actively warning of a possible exit scam due to the extended presale timeline and technical barriers preventing token access.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement TuHURA Biosciences Regains Compliance with Nasdaq Minimum Bid Price Requirement PR Newswire TAMPA, Fla., Feb. 27, 2026...

TuHURA Biosciences Announces Participation in Upcoming Investor Conferences

TuHURA Biosciences Announces Participation in Upcoming Investor Conferences TuHURA Biosciences Announces Participation in Upcoming Investor Conferences PR Newswire TAMPA, Fla., Feb. 24, 2026 TAMPA...

TuHURA Biosciences (HURA) to Release Earnings on Wednesday

TuHURA Biosciences (NASDAQ:HURA) will be releasing earnings before the market opens on Wednesday, February 25. (View Earnings Report at...

TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers

TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of Blood-Related Cancers TuHURA Files Investigational New Drug Application for TBS-2025 in the Treatment of...

TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference TuHURA Biosciences to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference PR...

<ul class="summary-bullets"><li>Orphan drug status adds regulatory incentives and boosts visibility for IFx-2.0.</li><li>Early trial data showed the treatment was safe with signs of benefit.</li><li>The news reignited retail interest after recent analyst resets, pipeline updates, and a financing that extended the company’s development runway.</li></ul>Shares of TuHURA Biosciences drew intense retail chatter on Tuesday after the company said the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to its melanoma therapy.<h2 class="st-heading-2">FDA Orphan Drug Designation For IFx-2.0</h2>TuHURA said the FDA’s Office of Orphan Products Development granted Orphan Drug Designation to IFx-2.0 for the treatment of stage IIB to stage IV cutaneous melanoma. The designation is based on data from a previously completed Phase 1 study, which showed IFx-2.0 was safe with no serious dose-limiting toxicities.The study also&nbsp;found that some patients whose cancers had stopped responding to prior immunotherapy later responded when treated with standard immune checkpoint inhibitors.Orphan Drug Designation provides seven years of market exclusivity upon approval, along with tax credits for certain research costs, access to FDA grants, better regulatory guidance, and a waiver of New Drug Application user fees.TuHURA said its near-term focus remains on completing enrollment in its Phase 3 trial of IFx-2.0 in combination with Keytruda for first-line treatment of advanced or metastatic Merkel cell carcinoma.<h2 class="st-heading-2">Portfolio Updates</h2>In December, TuHURA announced the release of contingent value rights tied to legacy Kintara Therapeutics assets after a REM-001 clinical trial in metastatic cutaneous breast cancer met its primary endpoint, demonstrating safety and signs of clinical efficacy. The milestone triggered the release of more than 1.5 million TuHURA shares to former Kintara stockholders under the CVR agreement.Additionally, the company highlighted early research and patient-related data supporting its experimental antibody, TBS-2025, which it said showed survival benefits, particularly when used alongside standard chemotherapy or other targeted treatments.TuHURA also said a recently completed financing, which raised $15.6 million in gross proceeds, is expected to fund key milestones across its three development programs, including IFx-2.0, TBS-2025, and earlier-stage immune-modulating platforms.Last month,&nbsp; H.C. Wainwright lowered its price target on TuHURA to $10 from $12 while maintaining a ‘Buy’ rating. The brokerage said at the time that upcoming value inflection points, combined with a recent decline in the stock, created what he described as an attractive entry point for investors.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for TuHURA was ‘bullish’ amid a 7,300% surge in 24-hour message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/hura_ss_png_6d663076c8.webp" alt="hura ss.png" width="971" height="139"><figcaption>HURA sentiment and message volume as of February 3 | Source: Stocktwits</figcaption></figure>One user called the fall in stock price a “real loading zone.”<stembedurl>https://stocktwits.com/Gotsomescrewsmissing/message/643709473</stembedurl>Another trader suggested the company’s latest capital raise could wrap up much earlier than expected.<stembedurl>https://stocktwits.com/Gotsomescrewsmissing/message/643695662</stembedurl><a href="https://stocktwits.com/symbol/HURA">TuHURA’s stock</a> has declined 90% over the past 12 months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

TuHURA’s stock has declined 90% over the past 12 months. (Representative Image: Getty Images)

This Small-Cap Biotech Stock Has Sparked A 7,000% Surge In Retail Chatter — Here’s Why

Hura Stock - The company is focused on completing enrollment in its Phase 3 IFx-2.0 study with Keytruda for advanced Merkel cell carcinoma.

HURA Stock Sparks 7,000% Surge In Retail Chatter After FDA Orphan Drug Win For Melanoma Therapy

Equity

The company is focused on completing enrollment in its Phase 3 IFx-2.0 study with Keytruda for advanced Merkel cell carcinoma.

TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone

TuHURA Biosciences Announces its Release of Kintara's Contingent Value Right (CVR) as Kintara's REM-001 Meets Primary Safety Endpoint Achieving Contractual Milestone TuHURA Biosciences Announces its...

TuHURA Biosciences (NASDAQ:HURA) Rating Lowered to Sell at Wall Street Zen

Wall Street Zen cut TuHURA Biosciences from a "hold" rating to a "sell" rating in a research report on Sunday...

TuHURA Biosciences Provides Corporate Update Following Recent Financing

TuHURA Biosciences Provides Corporate Update Following Recent Financing TuHURA Biosciences Provides Corporate Update Following Recent Financing PR Newswire TAMPA, Fla., Dec. 11, 2025 Company's lead...

TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering

TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering TuHURA Biosciences, Inc. Announces $15.6 Million Registered Direct Offering PR Newswire TAMPA, Fla., Dec. 9, 2025 TAMPA...

This account has been verified as an official HURA representative.

Verified Account

Tu HURA IR

TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company, which engages in the development of novel technologies to overcome resistance to cancer immunotherapy. The firm’s lead product candidate, IFx2.0, is an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. The company was founded on May 4, 2023 and is headquartered in Tampa, FL.

Current Price	$1.90
Prev Close	$1.96
Open	$2.00
Dividend Yield	0.00%
50-Day Moving Average	$1.05
Beta	0.51
Avg. Volume	4.11M
PE Ratio	-2.93

52-Week High	$4.44
52-Week Low	$0.41
Market Capitalization	$119.01M
EPS (Annual)	-$1.21
Price to Book	5.90
Revenue Per Employee	$0.00

HURA
TuHURA Biosciences Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest HURA News

HURATuHURA Biosciences Inc.